Pressure BioSciences, Inc. (OTCQB:PBIO) ships of the Company’s first commercial production lot of a revolutionary nanoemulsion product created and enabled by the Company’s innovative Ultra Shear Technology™ . The product is a breakthrough CBD oral spray designed by PBI for fast effect and high potency for Safer Medical of Montana. A $75,000 Pilot Lot Payment Received for Phase I of Safer Medical of Montana Agreement; Phases II/III Commercial Scale-Up Scheduled for Early 2023 – Expected to Yield 1st Half 2023 Revenues Over $1 Million.
On Wednesday, PBIO stock moved down 1.54% at $1.28 with more than 3.4K shares, compared to its average volume of 14K shares. The stock moved within a range of $1.2800 – 1.3000 after opening trade at $1.30.
Pressure based instruments developer and manufacturer Pressure Biosciences Inc (OTCMKTS:PBIO) is one of the more interesting companies that investors could consider keeping an eye on over the coming days.
The company was in the news yesterday after it announced that it had been successful in sending out the first shipment of a highly innovative nanoemulsion product. However, more importantly, the product had actually been created by the company through its revolutionary Ultra Shear Technology nano emulsification platform.
While that is a milestone in itself, it is also important for investors to take a look at the actual product that had been shipped by the company. The product in question is a CBD oral spray that boasts of considerable potency and quick effect for Safer Medical of Montana. It should be noted that Pressure Biosciences had signed a manufacturing and development agreement with Safer Medical of Montana.
As per the nature of the agreement that Pressure Biosciences had signed, the company would be responsible for the commercialization and development of the oral spray made from customized hemp-derived nano emulsified CBD. The founder and Chief Executive Officer of Safer Medical of Montana Captain George Ackerman spoke about the development as well.
He stated that Safer Medical’s executives were highly excited at the possibility of partnering with Pressure BioSciences. This was another significant milestone for Pressure Biosciences as a company and it is going to be interesting to see if the stock can manage to come into focus among investors or not.
PBIO stock is trading above the 20-Day and 50-Day Moving averages of $1.24 and $1.23 respectively. However, the stock is trading below the 200-Day moving average of $1.59.